Pivotal biomarker expression and drug screening in advanced ccRCC
Pivotal biomarker expression and drug screening in advanced ccRCC
复制标题
晚期 ccRCC 的关键生物标志物表达和药物筛选
DOI：
10.1002/ctm2.114
复制
发表时间：
2020-06
影响因子：
10.6
通讯作者：
Zhang Xiaoping
中科院分区：
文献类型：
--
作者：
Xiao Wen;Chen Ke;Zhang Xiaoping
尊敬的编辑：我们之前的研究结果表明，减少脂质积累，称为“肿瘤减肥”，可以抑制肿瘤细胞的生长和转移，1，2而我们几乎没有发现药物直接影响肾癌细胞的减肥。本研究通过复杂的生物信息学方法筛选出9种关键生物标志物和几种小分子药物，为临床晚期肾癌的诊断和治疗提供参考。肾透明细胞癌（ccRCC）是最常见的癌症之一，在具有明显异常脂质蓄积的肾癌中病死率最高，3尽管脂质蓄积的机制和作用尚不完全清楚。明确肿瘤的病理类型和病理分级对肿瘤患者的治疗具有重要意义。根据临床诊断标志物的结果调整治疗，对患者的预后有积极影响。由于缺乏肾癌的特异性肿瘤标志物，当疾病最初通过成像诊断时，癌症已经转移。因此，寻找有效的生物标志物对肾癌的治疗具有重要意义。早期肾癌行局部或根治性肾切除术后仍有较高的局部复发或远处转移风险。4酪氨酸激酶抑制剂（Tyrosine kinase inhibitor，TKI）是治疗晚期肾癌的常用药物，但对生存期的预后影响不大. 5细胞周期调控和细胞粘附维持可促进肿瘤细胞的发生和发展。6上皮间质转化（EMT）在肿瘤进展和耐药中具有重要的临床意义. 7 TKI可抑制肿瘤细胞周期和EMT，影响肿瘤生长。8不幸的是，TKI耐药性发展并导致ccRCC进展不良。迫切需要探索更有效的预后生物标志物并了解其作用机制，以确定新的ccRCC治疗的新药靶点。我们对晚期ccRCC的GSE 150404数据集进行了深入分析，其中包含四个等级，
Dear Editor, Our previous results demonstrated that reducing lipid accumulation, called “Tumor Slimming,” can inhibit the growth and metastasis of tumor cells, 1, 2 whereas we have hardly found drugs to directly affect the slimming of renal cancer cells. Here, we identified nine pivotal biomarkers and several small molecule drugs with complex bioinformatics methods, which may be helpful for clinical diagnosis and treatment for advanced renal cell carcinoma. Renal clear cell carcinoma (ccRCC) is one of the most common cancers, with the highest fatality rate in renal cancer with obvious abnormal lipid accumulation, 3 although the mechanism and role of lipid accumulation are not fully known. Clarifications of pathological type and pathological grade are important for the cancer patient management. The treatment is adjusted according to the results of clinical diagnostic markers, with positive effects on the prognosis of patients. Due to the lack of specific tumor markers for renal cancer, cancers were metastasized when the disease was initially diagnosed with imaging. Therefore, the discover of effective biomarker is important for the treatment of renal cancer. There is still a high risk of local recurrence or distant metastasis after local or radical nephrectomies for early renal cancer. 4 Tyrosine kinase inhibitor (TKI) drugs are generally used for the treatment of advanced renal cancer, but still have poor effects on prognosis of thesurvival. 5 Cell cycle regulation and cell adhesion maintenance can promote the occurrence and development of tumor cells. 6 Epithelialmesenchymal transition (EMT) has an important clinical significance for cancer progression and drug resistance. 7 TKI can inhibit tumor cell cycle and EMT to affect tumor growth. 8 Unfortunately, TKI resistance developed and lead to poor progression in ccRCC. There is an urgent need to explore more effective prognostic biomarkers and understand the mechanism of the effects in order to determine new drug targets for new ccRCC treatment. We performed a deep analysis of GSE150404 dataset for advanced ccRCC, which contained four grades with 15
登录
查看更多内容
影响因子：
158.5
作者：
Ravaud, A.;Motzer, R. J.;Patard, J. -J.
通讯作者：
Patard, J. -J.
影响因子：
20.3
作者：
Chen, Yang;Wang, Shan;Luo, Yongzhang
通讯作者：
Luo, Yongzhang
影响因子：
64.8
作者：
Chen W;Hill H;Christie A;Kim MS;Holloman E;Pavia-Jimenez A;Homayoun F;Ma Y;Patel N;Yell P;Hao G;Yousuf Q;Joyce A;Pedrosa I;Geiger H;Zhang H;Chang J;Gardner KH;Bruick RK;Reeves C;Hwang TH;Courtney K;Frenkel E;Sun X;Zojwalla N;Wong T;Rizzi JP;Wallace EM;Josey JA;Xie Y;Xie XJ;Kapur P;McKay RM;Brugarolas J
通讯作者：
Brugarolas J
肿瘤细胞“瘦身”通过 PLCL1/UCP1 介导的脂质褐变调节肿瘤进展
影响因子：
15.1
作者：
Xiong, Zhiyong;Xiao, Wen;Zhang, Xiaoping
通讯作者：
Zhang, Xiaoping
影响因子：
28.2
作者：
Qiu B;Ackerman D;Sanchez DJ;Li B;Ochocki JD;Grazioli A;Bobrovnikova-Marjon E;Diehl JA;Keith B;Simon MC
通讯作者：
Simon MC